Table 1.
IC50 values for ACA and its analogs on various cancer cell lines and normal cells
| Cell lines | IC50 (μM)
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ACA | 2 | 5 | 6 | 7 | 8 | AEA | AMCA | 19 | 20 | |
| Breast adenocarcinoma (MDA-MB-231) | 4.8±0.4 | N/A | N/A | N/A | N/A | N/A | 9.5±0.3 | 29.6±5.6 | N/A | N/A |
| Breast adenocarcinoma (MCF-7) | 30.0±0.3 | N/A | N/A | N/A | N/A | N/A | 25.2±0.6 | N/A | N/A | N/A |
| Bladder carcinoma (RT-112) | 14.1±3.8 | N/A | N/A | N/A | N/A | N/A | 10.9±2.4 | N/A | N/A | N/A |
| Bladder carcinoma (EJ-28) | 8.2±0.9 | N/A | N/A | N/A | N/A | N/A | 4.2±2.2 | N/A | N/A | N/A |
| Prostate carcinoma (PC-3) | 26.7±2.3 | N/A | N/A | N/A | N/A | N/A | 13.8±0.8 | N/A | N/A | N/A |
| Oral squamous carcinoma (HSC-4) | 5.5±0.5 | N/A | N/A | N/A | N/A | N/A | 5.1±0.2 | N/A | N/A | N/A |
| Hepatocyte carcinoma (HepG2) | 18.0±0.8 | N/A | N/A | N/A | N/A | N/A | 4.3±0.5 | N/A | N/A | N/A |
| HMECs | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Notes: Cells were treated with the test compounds for 24 h. Data are reported as mean ± SEM (n=3). N/A denotes that cell viability levels were maintained above 50% at maximum concentration of test compound (50 μM) at 24 h of incubation.
Abbreviations: ACA, 1′S-1′-acetoxychavicol acetate; AEA, 1′-acetoxyeugenol acetate; AMCA, 1′-acetoxy-3,5-dimethoxychavicol acetate; HMECs, human mammary epithelial cells; IC50, half-maximal inhibitory concentration; SEM, standard error of the mean; N/A, not applicable.